Anavex/$AVXL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Anavex
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Ticker
$AVXL
Sector
Primary listing
Employees
34
Headquarters
Website
Anavex Metrics
BasicAdvanced
$393M
-
-$0.54
1.10
-
Price and volume
Market cap
$393M
Beta
1.1
52-week high
$14.44
52-week low
$2.86
Average daily volume
3.4M
Financial strength
Current ratio
11.605
Quick ratio
11.557
Profitability
Management effectiveness
Return on assets (TTM)
-26.51%
Return on equity (TTM)
-43.11%
Valuation
Price to book
4.02
Price to tangible book (TTM)
4.02
Price to free cash flow (TTM)
-9.612
Free cash flow yield (TTM)
-10.40%
Free cash flow per share (TTM)
-0.458
Growth
Earnings per share change (TTM)
5.55%
3-year earnings per share growth (CAGR)
-4.48%
10-year earnings per share growth (CAGR)
-1.79%
What the Analysts think about Anavex
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Anavex Financial Performance
Revenues and expenses
Anavex Earnings Performance
Company profitability
Anavex News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $393M as of December 07, 2025.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of December 07, 2025.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of December 07, 2025.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.